Head to head
DRUGS MADE IN AMERICA ACQ II CORP vs Vylor Inc
Side-by-side on the measures that matter, with a plain-English read. Full detail: DMII · VYLR
DMII
DRUGS MADE IN AMERICA ACQ II CORP
10.23-0.20%
1-year price shape — not enough history yet
Quant Rating C · 0/100
vs
VYLR
Vylor Inc
68.09+0.47%
1-year price shape — not enough history yet
Quant Rating C · 0/100
1-year performance, rebased to 100
Vylor Inc edges it on the scoreable measures. Vylor Inc earns the most per share.
| DMII | VYLR | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Shell Companies |
| Last price | 10.23 | 68.09 |
| Change today | -0.20% | +0.47% |
| 1-year return | -- | -- |
| Market cap | $651.65M | $45.44B |
| 52-week range | 9.86 – 10.33 | 65.00 – 77.39 |
| Valuation | ||
| P/E (TTM) | 27.65 | 96.04 |
| P/E percentile, own 5-yr range | 65th | 55th |
| P/B | 1.30 | 2.99 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 0.15 | 0.56 |
| Net profit (TTM) | $9.56M | $376.36M |
| Revenue (TTM) | $0 | -- |
| Provider revenue period date | 2026-06-29 | 2026-09-29 |
| Revenue growth (YoY) | -- | -- |
| Gross margin | -- | 54.5% |
| Operating margin | -- | 18.7% |
| Net margin | -- | 4.5% |
| Free cash flow (TTM) | $-1.28M | -- |
| Provider cash-flow period date | 2026-06-29 | 2026-03-30 |
| Ownership & sentiment | ||
| Institutional ownership | 76.2% | 24.0% |
| Insider activity (12mo) | 6 buy / 2 sell | 38 buy / 10 sell |
| Short interest (% of float) | 0.2% | 2.1% |
| Analyst consensus | -- | 78% buy / 22% hold (9) |
| Analyst price target | -- | $83 (+23%) |
| StockVane view | ||
| StockVane Quant Rating | C (0) | C (0) |
| Company | ||
| Employees | 2 | -- |
| Founded | -- | 2025 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.